Yes, absolutely! Should be AML!
@21391401 I am expecting results by Q4. It may be earlier or later than this.
@SMN888 My understanding is as follows:
P2 AML: 5-day 250 mg/m2/d Bis in combination with clofarabine and fludarabine. Unsure if receiving a follow-up dose.
P2 EMD AML: Stratum 1: 7-day 250 mg/m2/d single agent Bis induction with 3-day Bis + cytarabine combination in non-responders (IIRC).
Stratum 2: ~possibly 50 mg/m2 Bis 3x per week or every other day for an unknown amount of time in combination with decitabine.
P2 BC trial: Single bolus 320 mg/m2 once every three weeks.
Personally, I would love to see the BC trial done differently, but RAC have to follow the historic trials. What is in our favor for these trials is the patient population should be more applicable for Bisantrene based on the compelling preclinical data - metastatic & resistant to other therapies.
RAC Primer, page-452
-
- There are more pages in this discussion • 70 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $288.0M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.69 | $1.57 | $387.6K | 237.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 807 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 2376 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |